Riverbridge Partners LLC Sells 3,246 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Riverbridge Partners LLC decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 116,365 shares of the company's stock after selling 3,246 shares during the quarter. Riverbridge Partners LLC owned about 0.14% of IDEXX Laboratories worth $64,589,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the company. Gray Wealth Management Inc. lifted its position in shares of IDEXX Laboratories by 3.3% in the 2nd quarter. Gray Wealth Management Inc. now owns 619 shares of the company's stock worth $311,000 after acquiring an additional 20 shares during the period. Patron Partners LLC lifted its position in shares of IDEXX Laboratories by 2.7% in the 4th quarter. Patron Partners LLC now owns 765 shares of the company's stock worth $425,000 after acquiring an additional 20 shares during the period. American Trust lifted its position in shares of IDEXX Laboratories by 5.1% in the 2nd quarter. American Trust now owns 431 shares of the company's stock worth $216,000 after acquiring an additional 21 shares during the period. Phoenix Holdings Ltd. lifted its position in shares of IDEXX Laboratories by 2.8% in the 3rd quarter. Phoenix Holdings Ltd. now owns 769 shares of the company's stock worth $338,000 after acquiring an additional 21 shares during the period. Finally, BluePath Capital Management LLC lifted its position in shares of IDEXX Laboratories by 1.8% in the 4th quarter. BluePath Capital Management LLC now owns 1,197 shares of the company's stock worth $663,000 after acquiring an additional 21 shares during the period. Institutional investors own 87.84% of the company's stock.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the transaction, the chief executive officer now directly owns 79,247 shares in the company, valued at approximately $45,377,624.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm's stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the transaction, the chief executive officer now directly owns 79,247 shares in the company, valued at approximately $45,377,624.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP George Fennell sold 8,198 shares of the firm's stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares in the company, valued at $3,851,815.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,524 shares of company stock worth $24,871,960. Insiders own 2.11% of the company's stock.

IDEXX Laboratories Price Performance

IDXX stock traded down $5.94 during midday trading on Thursday, reaching $518.10. 353,962 shares of the company's stock traded hands, compared to its average volume of 423,044. The company has a 50-day simple moving average of $548.76 and a two-hundred day simple moving average of $504.38. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39. The company has a market cap of $43.03 billion, a price-to-earnings ratio of 51.45, a PEG ratio of 2.86 and a beta of 1.26. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating analysts' consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The business's quarterly revenue was up 8.8% compared to the same quarter last year. During the same period last year, the company earned $2.05 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on IDXX shares. Barclays raised their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 6th. StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Wednesday, December 20th. William Blair reissued an "outperform" rating on shares of IDEXX Laboratories in a report on Friday, January 5th. BNP Paribas assumed coverage on IDEXX Laboratories in a report on Thursday, December 7th. They issued an "outperform" rating and a $602.00 target price for the company. Finally, Piper Sandler cut IDEXX Laboratories from an "overweight" rating to a "neutral" rating and set a $525.00 target price for the company. in a report on Tuesday, January 30th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $591.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.